Jazz Pharma's Zanidatamab Granted FDA Priority Review for Advanced HER2-Positive Biliary Tract Cancer
Portfolio Pulse from Benzinga Newsdesk
Jazz Pharmaceuticals' zanidatamab has been granted FDA Priority Review for the treatment of advanced HER2-positive biliary tract cancer. The FDA has set a target action date of November 29, 2024.
May 29, 2024 | 11:47 am
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Jazz Pharmaceuticals' zanidatamab has been granted FDA Priority Review for the treatment of advanced HER2-positive biliary tract cancer. The FDA has set a target action date of November 29, 2024.
The FDA Priority Review status for zanidatamab is a significant milestone for Jazz Pharmaceuticals, indicating the potential for an expedited approval process. This could lead to increased investor confidence and a positive short-term impact on the stock price.
CONFIDENCE 95
IMPORTANCE 90
RELEVANCE 100